A Monoclonal Antibody Panel to Track Antigenic Evolution of SARS-CoV-2 JN.1 Subvariants
- 1Columbia University Irving Medical Center
Abstract
SARS-CoV-2 continues to evolve, generating successive variants with enhanced resistance to antibody-mediated neutralization. However, many existing monoclonal antibody (mAb) repertoires were derived from ancestral or early Omicron strains and have lost activity against contemporary variants, limiting their ability to resolve the antigenic effects of mutations arising in newly emerging lineages. Here, we generated a mAb panel by immunizing naive, unimprinted VelocImmune humanized mice with spike from the KP.3.1.1 variant, and isolated and characterized 11 neutralizing antibodies targeting diverse epitopes of recently evolved antigenic variants. We then integrated these antibodies with previously characterized mAbs to establish an expanded toolbox for profiling antigenic evolution among emerging variants. Application of this panel to currently emerging SARS-CoV-2 variants provided mechanistic insight into recent antigenic evolution, highlighting the potential role of altered receptor-binding domain conformation. Our data also revealed clear differences in antibody-evasion profiles between JN.1-derived lineages and BA.3.2 lineages. Together, our findings establish an updated mAb panel for monitoring antigenic evolution of JN.1 subvariants.
Related
- A Panel of Human Monoclonal Antibodies for Tracking the Antigenic Evolution of Influenza H5N1 Clade 2.3.4.4b
- Near real-time data on the human neutralizing antibody landscape to influenza virus in summer of 2026 shows antigenic advance of H3N2 subclade K region D mutants and H1N1 D.3.1.1 Sa mutants
- Geometry of antigenic evolution improves influenza vaccine selection
- Prevalence and the rate of antigenic evolution are jointly determined in an eco-evolutionary SIR model
- Antigenic landscape of a highly mutated SARS-CoV-2 spike in ongoing viral evolution
BibTeX
@misc{hong2026monoclonal,
title = {{A Monoclonal Antibody Panel to Track Antigenic Evolution of SARS-CoV-2 JN.1 Subvariants}},
author = {H. Hong and M. Wu and S. Chong and J. Yu and I. A. Mellis and C.-Y. Huang and Q. Wang and Y. Huang and Y. Guo and D. D. Ho},
howpublished = {bioRxiv},
year = {2026},
month = may,
doi = {10.64898/2026.05.29.728770},
url = {https://www.biorxiv.org/content/10.64898/2026.05.29.728770v2},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - A Monoclonal Antibody Panel to Track Antigenic Evolution of SARS-CoV-2 JN.1 Subvariants
AU - H. Hong
AU - M. Wu
AU - S. Chong
AU - J. Yu
AU - I. A. Mellis
AU - C.-Y. Huang
AU - Q. Wang
AU - Y. Huang
AU - Y. Guo
AU - D. D. Ho
PY - 2026
DA - 2026/05/29
PB - bioRxiv
DO - 10.64898/2026.05.29.728770
UR - https://www.biorxiv.org/content/10.64898/2026.05.29.728770v2
AB - SARS-CoV-2 continues to evolve, generating successive variants with enhanced resistance to antibody-mediated neutralization. However, many existing monoclonal antibody (mAb) repertoires were derived from ancestral or early Omicron strains and have lost activity against contemporary variants, limiting their ability to resolve the antigenic effects of mutations arising in newly emerging lineages. Here, we generated a mAb panel by immunizing naive, unimprinted VelocImmune humanized mice with spike from the KP.3.1.1 variant, and isolated and characterized 11 neutralizing antibodies targeting diverse epitopes of recently evolved antigenic variants. We then integrated these antibodies with previously characterized mAbs to establish an expanded toolbox for profiling antigenic evolution among emerging variants. Application of this panel to currently emerging SARS-CoV-2 variants provided mechanistic insight into recent antigenic evolution, highlighting the potential role of altered receptor-binding domain conformation. Our data also revealed clear differences in antibody-evasion profiles between JN.1-derived lineages and BA.3.2 lineages. Together, our findings establish an updated mAb panel for monitoring antigenic evolution of JN.1 subvariants.
ER -